Eagle Pharmaceuticals

243 articles with Eagle Pharmaceuticals

• Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

  12/20/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.

• Eagle Pharmaceuticals Receives FDA Approval for Vasopressin

  12/15/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug application (“ANDA”) for vasopressin.

• Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

  11/22/2021

  Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

• Eagle Pharmaceuticals Reports Third Quarter 2021 Results

  11/9/2021

  Eagle Pharmaceuticals Reports Third Quarter 2021 Results

• Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021

  10/28/2021

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens.

• Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021

  9/7/2021

  Eagle Pharmaceuticals, Inc. will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:.

• Eagle Pharmaceuticals to Present at September Healthcare Conferences

  9/1/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences.

• Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

  8/31/2021

  Eagle Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled “Formulations of Bendamustine.” Eagle is submitting the ‘483 patent for listing in the U.S. Food and Drug Administration’s Orange Book for both BENDEKA® and BELRAPZO®.

• Eagle Pharmaceuticals Wins Vasopressin Patent Trial

  8/31/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company.

• Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

  8/25/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA

• Eagle Pharmaceuticals Reports Second Quarter 2021 Results

  8/9/2021

  Eagle Pharmaceuticals, Inc. announced financial results for the three and six months ended June 30, 2021.

• Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker

  8/9/2021

  Eagle Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH, a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States.

• Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021

  7/28/2021

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens.

• Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin

  6/24/2021

  Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug and Administration has maintained Priority Review for the Company’s Abbreviated New Drug Application for vasopressin.

• Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin

  6/17/2021

  Eagle Pharmaceuticals, Inc. announced that it has responded to the Complete Response Letter for its Abbreviated New Drug Application for vasopressin received from the U.S. Food and Drug Administration in February 2021.

• Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

  5/26/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021

•  Eagle Pharmaceuticals Reports First Quarter 2021 Results

  5/10/2021

  Expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations

• Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan

  5/10/2021

  Eagle expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations

• Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

  5/3/2021

  Eagle Pharmaceuticals, Inc. announced the appointment of Luciana Borio, MD, to its Board of Directors.

• Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation

  4/30/2021

  -Eagle believes new indication could allow for a significant expansion of the overall market opportunity- -RTD and Rapid Infusion (“RI”) formulations anticipated to generate approximately $25 million of combined royalty and milestone revenue at peak-